Valid-screen 666800) and Self-screen BV. The latter sponsor was responsible for developing the protocol in collaboration with the other study investigators. The sponsor oversaw all aspects of the study conduct, including data management, statistical analysis, and reporting of results. All authors reviewed the data and approved to submit for publication.
| Study design
Agreement analysis for the QIAsure Methylation Test was performed on hrHPV-positive cervical specimens. Three independent agreement measures were completed.
• Intra-laboratory agreement of the QIAsure Methylation Test was determined at the reference laboratory by testing bisulfite-converted DNA from 584 cervical specimens originating from the reference laboratory with subsequent repeat testing of the bisulfite-converted DNA.
• Inter-laboratory agreement was determined on 399 cervical specimens obtained from one of the external participating centers, and bisulfite-converted DNA was shipped and subsequently tested in the reference laboratory.
• Additionally, given that the bisulfite conversion prior to the methylation testing may influence the assay outcome, the full laboratory workflow was analyzed for inter-laboratory agreement. For this, each participating laboratory used DNA from cervical specimens from their local study cohort (for numbers, see Table 1) and performed the full workflow. After completion of the testing, DNA of the analyzed samples was sent to the reference laboratory for retesting which included the bisulfite conversion step.
For precision testing, a control sample (QSC1) was incorporated into each test run in all the laboratories, including the bisulfite conversion.
All participating partner laboratories did not have previous experience with qMSP but underwent training on the QIAsure Methylation Test system prior to the start of study.
| Specimens
In total, 1680 hrHPV-positive cervical specimens were analyzed with the QIAsure Methylation Test. The cervical specimens originated from local cohorts organized by the seven different European centers and laboratories and collected in concordance with individual national or regional requirements, due process of governance, and local ethical guidelines. Details about specimen collection medium, handling, numbers per institute, and study setting are outlined in Table 1 . Specimens with sufficient leftover material were randomly selected from local cohorts. It was verified within each test situation that the QIAsure Methylation Test positivity rate was comparable to the known positivity rate in an HPV-positive screening cohort, 9 
| Histology data
Histology data were obtained from the local registries. Histological examination was done locally, and specimens were classified as normal (CIN0), CIN1, CIN2, CIN3, or invasive cancer, according to international criteria. 11 Of the 399 samples included in inter-laboratory assay agreement analysis (ie, test situation 2), all had histology data available. Of the 697 samples used for inter-laboratory workflow agreement analysis (ie, test situation 3), histology data were available for 373 specimens.
| Bisulfite conversion
Bisulfite conversion was performed with the EZ DNA Methylation kit (Zymo Research) according to the manufacturer's specifications. Standard DNA input for bisulfite conversion was 250 ng.
Elution was done with 12.5 µL M-elution buffer yielding 20 ng/µL bisulfite-converted DNA. For samples with insufficient DNA yield to accomplish an input of 250 ng (16% of the samples; ranging from 0% to 46% per laboratory), a minimal input of 100 ng was used.
| QIAsure methylation test
The QIAsure Methylation Test was performed according to the 
| Statistics
For all settings, test results were blinded and concordance analy- 
| Inter-laboratory agreement
DNA from a total of 399 cervical specimens was bisulfite-con- with a κ = 0.76, corresponding with a good agreement ( Table 4 ).
| Intra-and inter-laboratory precision of the control sample
A total of 220 measurements were available for the control sample QSC1, ranging from 12 to 97 measurements per laboratory. Overall, the mean and the standard deviation for the ΔΔCt values were 8.46
and 0.49 for FAM19A4, respectively, and 7.90 and 0.80 for hsa-mir124-2, respectively ( Table 5 ).
| Discrepancy analysis
For intra-laboratory assay agreement, 50 out of 584 samples ( 
| Histology stratification
The mean ΔΔCt values for the two markers were calculated for the different histology grades (whenever histology data were available).
Looking at the full workflow, the methylation levels increased with disease severity, resulting in the lowest mean ΔΔCt values for cancer: 7.2 for FAM19A4 and 6.7 for hsa-mir124-2; and the highest mean
ΔΔCt values for samples with no (evidence of) disease: 13.0 for FAM19A4 and 10.4 for hsa-mir124-2 (Table 6 ). Samples with CIN1 or CIN2 were in the middle of the spectrum and closer to the assay cutoff. Cancer cases, CIN3, and normal samples were at the outer ends of the spectrum and showed highest agreement values of 100%, 95%, and 92%, respectively ( Table 7) . For sole QIAsure Methylation
Test data, a similar trend was observed, although less pronounced (Table 7) .
| D ISCUSS I ON
We evaluated the intra-and inter-laboratory agreement of The present study confirms that the QIAsure Methylation Test is a reproducible test, which is a key parameter when considering its application in cervical screening. When applying the minimal intra-and inter-laboratory reproducibility criteria from the guidelines for primary HPV DNA test requirements, 12 the lower confidence bound for agreement and kappa value in this study are above the threshold of 87% and 0.5, respectively, for intra-laboratory and may not directly be applied to other molecular markers (such as methylation markers), the QIAsure Methylation Test complies with the criteria, supporting robustness of the assay.
After stratification for histology, agreement was the highest among women with cancer (100%, 3/3), followed by CIN3 (95%, 39/41; and 96%, 72/75) and normal histology (92%, 206/225; and 93%, 149/161). This represents true-positive and true-negative sample groups characterized by methylation levels most distanced from the assay cutoff. Discordance in test outcome was predominantly associated with methylation levels around the assay cutoff, which is known to be prone to variation, and this observation is consistent with other studies using diagnostic assays with binary output. 13, 14 Of note, the participating test laboratories did not have previous experience with methylation testing and many practical variables were included ( 
